Peter Smith, Remix Therapeutics CEO
May 17, 2022 06:45 AM EDTUpdated 08:24 AM
Financing

Fol­low­ing po­ten­tial bil­lion-dol­lar J&J deal, RNA pro­cess­ing biotech Remix re­turns with fresh fi­nanc­ing

Lei Lei Wu

News Reporter

A few months ago, Remix Ther­a­peu­tics penned a deal with John­son & John­son that could end up be­ing worth more than $1 bil­lion dol­lars down …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times